{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-001525","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.791747+00:00","generated_at":"2026-05-17T06:13:27.616989+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met","bullets":["All 27 patients completed 4-week treatment; no serious adverse events reported.","76% of tacrolimus blood measurements undetectable (<1.0 ng/mL); dry mouth in 18.5%.","Statistically significant improvements (p<0.05) in IGA, REU, pain, sensitivity, and OLPSSM at week 4.","Company advancing LP-10 into Phase 2b; preparing protocol with FDA feedback."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-001525","json":"https://secwatch.observer/filing/0001753926-25-001525.json","markdown":"https://secwatch.observer/filing/0001753926-25-001525.md","text":"https://secwatch.observer/filing/0001753926-25-001525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/0001753926-25-001525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/g084955_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:13:27.616989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}